These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 825590

  • 1. Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
    Mathias RG, Ronald AR, Gurwith MJ, McCullough DW, Stiver HG, Berger J, Cates CY, Fox LM, Lank BA.
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-401. PubMed ID: 825590
    [Abstract] [Full Text] [Related]

  • 2. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP, Louie TJ, O'Keefe P, Gorbach SL, Bartlett JG.
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [Abstract] [Full Text] [Related]

  • 3. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W, Reindke B, Versmold H.
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM, McGee ZA, Alford RH.
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.
    Lode H, Grunert K, Koeppe P, Langmaack H.
    J Infect Dis; 1976 Nov; 134 SUPPL():S316-22. PubMed ID: 825589
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF, Maslow MJ, Leibowitz RE, Pollock AA, Hanna BA, Schaefler S, Simberkoff MS, Rahal JJ.
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM, de Jongh CA, Schimpff SC, Tillman GL.
    JAMA; 1982 Sep 10; 248(10):1199-202. PubMed ID: 6809965
    [Abstract] [Full Text] [Related]

  • 16. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP, Louie TJ, Weinstein WM, Bartlett JG, Gorbach SL.
    Ann Intern Med; 1975 Oct 10; 83(4):484-8. PubMed ID: 1101761
    [Abstract] [Full Text] [Related]

  • 17. Treatment of hospita-acquired infections with amikacin.
    Doughty SC, Martin RR, Greenberg SB.
    Am J Med; 1977 Jun 10; 62(6):889-93. PubMed ID: 868903
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.
    Yu VL, Rhame FS, Pesanti EL, Axline SG.
    JAMA; 1977 Aug 29; 238(9):943-7. PubMed ID: 328950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.